Skip to content Skip to footer

Adjuvant Treatment With Ribociclib Reduces Risk of Recurrence in Hormone Receptor–Positive, HER2-Negative, Early-Stage Breast Cancer

The addition of the CDK4/6 inhibitor ribociclib to endocrine therapy significantly improved invasive disease–free survival in women with hormone receptor–positive, HER2-negative, early-stage breast cancer. These results of the phase III NATALEE trial were reported by lead author Dennis J. Slamon, MD, PhD, Director of Clinical/Translational Research and Director of the Revlon/UCLA Women’s Cancer Research Program at the UCLA Jonsson Comprehensive Cancer Center, at the 2023 ASCO Annual Meeting.1 Of note, NATALEE included patients with node-negative and node-positive, early-stage breast cancer, unlike other recent trials in the adjuvant setting.

Share on Twitter Share on Facebook Share on LinkedIn Adding Ribociclib to Hormonal Therapy Reduces Risk of Recurrence for People With Most Common Subtype of Breast Cancer

ASCO Perspective 

“While early, these results are very promising and suggest that there will be a role for adjuvant ribociclib for stage II and higher hormone receptor-positive (HR-positive), HER2-negative breast cancer,” said Rita Nanda, MD, ASCO Expert. 

ALEXANDRIA, Va. — Adding the targeted therapy drug ribociclib (Kisqali®) to hormonal (endocrine) therapy showed a significant improvement in invasive disease-free survival (iDFS) for people with HR-positive, HER2-negative early-stage breast cancer. The research will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

HR-positive, HER2-negative breast cancer is the most common subtype of the disease, making up nearly 70% of all breast cancer cases in the United States.1

About us
Welcome to the Cancer and Blood Specialty Clinic (CBSC), a leading provider of comprehensive care for cancers and other blood disorders. Our team of highly trained and experienced hematologists and oncologists is dedicated to providing our patients with the best possible care, using the latest advances in medicine and technology.

3851 Katella Avenue, Los Alamitos, CA, USA


© 2023, All Rights Reserved. Powered by Destech International

Connect us

Our site uses cookies. Learn more about our use of cookies: cookie policy